

# 1 Proteomic blood profiling in mild, severe and critical COVID-19 patients

2 Hamel Patel<sup>1,2\*</sup>, Nicholas J Ashton<sup>3,4,5,6\*</sup>, Richard J.B Dobson<sup>1,2,7,8,9,10</sup>, Lars-Magnus  
3 Andersson<sup>11,12</sup>, Aylin Yilmaz<sup>11,12</sup>, Kaj Blennow<sup>3,13</sup>, Magnus Gisslen<sup>11,12</sup>, Henrik  
4 Zetterberg<sup>3,13,14,15</sup>

## 5 Affiliations

6 <sup>1</sup>Department of Biostatistics and Health Informatics, Institute of Psychiatry, Psychology and  
7 Neuroscience, King's College London, London, UK;

8 <sup>2</sup>NIHR BioResource Centre Maudsley, NIHR Maudsley Biomedical Research Centre (BRC)  
9 at South London and Maudsley NHS Foundation Trust (SLaM) & Institute of Psychiatry,  
10 Psychology and Neuroscience (IoPPN), King's College London;

11 <sup>3</sup>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The  
12 Sahlgrenska Academy, University of Gothenburg, Sweden;

13 <sup>4</sup>Wallenberg Centre for Molecular and Translational Medicine, Department of Psychiatry and  
14 Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the  
15 University of Gothenburg, Sweden;

16 <sup>5</sup>Department of Old Age Psychiatry, Institute of Psychiatry, Psychology & Neuroscience,  
17 King's College London, London, UK;

18 <sup>6</sup>NIHR Biomedical Research Centre for Mental Health & Biomedical Research Unit for  
19 Dementia at South London & Maudsley NHS Foundation, London, UK;

20 <sup>7</sup>UK Dementia Research Institute at UCL, London, UK;

21 <sup>8</sup>Health Data Research UK London, University College London, 222 Euston Road, London,  
22 UK;

23 <sup>9</sup>Institute of Health Informatics, University College London, 222 Euston Road, London, UK;

24 <sup>10</sup>The National Institute for Health Research University College London Hospitals Biomedical  
25 Research Centre, University College London, 222 Euston Road, London, UK;

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

26 <sup>11</sup>Department of Infectious Diseases, Institute of Biomedicine, Sahlgrenska Academy,  
27 University of Gothenburg, Gothenburg, Sweden;

28 <sup>12</sup> Region Västra Götaland, Sahlgrenska University Hospital, Department of Infectious  
29 Diseases, Gothenburg, Sweden;

30 <sup>13</sup> Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden;

31 <sup>14</sup> Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK;

32 <sup>15</sup>UK Dementia Research Institute at UCL, London, UK

33

34 \*Dr. Hamel Patel and Dr. Nicholas J Ashton are joint first authors.

35

36 **Corresponding authors:**

37 Hamel Patel, PhD, Department of Biostatistics and Health Informatics, NIHR Biomedical  
38 Research Centre for Mental Health, South London and Maudsley NHS Foundation Trust &  
39 Institute of Psychiatry, Kings College London, De Crespigny Park, London SE5 8AF (UK)  
40 ([hamel.patel@kcl.ac.uk](mailto:hamel.patel@kcl.ac.uk))

41

42 Nicholas James Ashton, PhD, University of Gothenburg, Department of Psychiatry and  
43 Neurochemistry, Wallenberg Centre for Molecular and Translational Medicine, MedTech  
44 West, Röda stråket 10B, Sahlgrenska University Hospital, 413 45 Göteborg (Sweden)  
45 ([nicholas.ashton@gu.se](mailto:nicholas.ashton@gu.se))

46 **Author contributions**

47 AY, LMA and MG were involved in patient recruitment. HP analyzed the data with input  
48 from NJA, RJBD, MG and HZ. HP developed the interactive web-based tool to host the

49 results from this study. HP and NJA drafted the manuscript with all authors contributing to  
50 the result interpretation and critical review of the manuscript.

51

## 52 **Abstract**

53 The recent SARS-CoV-2 pandemic manifests itself as a mild respiratory tract infection in the  
54 majority of individuals leading to COVID-19 disease. However, in some infected individuals,  
55 this can progress to severe pneumonia and acute respiratory distress syndrome (ARDS), leading  
56 to multi-organ failure and death. The purpose of this study is to explore the proteomic  
57 differences between mild, severe and critical COVID-19 positive patients. Blood protein  
58 profiling was performed on 59 COVID-19 mild (n=26), severe (n=9) or critical (n=24) cases  
59 and 28 controls using the OLINK inflammation, autoimmune, cardiovascular and neurology  
60 panels. Differential expression analysis was performed within and between disease groups to  
61 generate nine different analyses. From the 368 proteins measured per individual, more than  
62 75% were observed to be significantly perturbed in COVID-19 cases. Six proteins (IL6,  
63 CKAP4, Gal-9, IL-1ra, LILRB4 and PD-L1) were identified to be associated with disease  
64 severity. The results have been made readily available through an interactive web-based  
65 application for instant data exploration and visualization, and can be accessed at  
66 <https://phidatalab-shiny.rosalind.kcl.ac.uk/COVID19/>. Our results demonstrate that dynamic  
67 changes in blood proteins that associate with disease severity can potentially be used as early  
68 biomarkers to monitor disease severity in COVID-19 and serve as potential therapeutic targets.

69

## 70 **Introduction**

71 The recent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic  
72 manifests itself as a mild respiratory tract infection in the majority of individuals leading to  
73 coronavirus disease 2019 (COVID-19) disease. However, in some infected individuals, this

74 can progress to severe pneumonia and acute respiratory distress syndrome (ARDS), leading to  
75 multi-organ failure and death. The exact percentage of patients presenting with severe  
76 symptoms is currently impossible to calculate as the exact number of individuals who have  
77 contracted the virus is unknown and many who have, are unaware due to being asymptomatic.  
78 Nevertheless, according to the World Health Organization (WHO), it is estimated 80% of  
79 infections are asymptomatic or mild, 15% are severe infections requiring oxygen support, and  
80 5% are critical requiring ventilation (1).

81

82 SARS-CoV-2 shares an evolutionary relationship with SARS-CoV, the causative pathogen of  
83 the SARS outbreak in 2013 (2). Currently, owing to the lack of reliable markers, it is  
84 challenging to monitor individuals that are progressing to severe COVID-19, which relies  
85 mainly on clinical manifestations (3). Previous studies on highly pathogenic coronaviruses,  
86 e.g., SARS or Middle East Respiratory Syndrome (MERS), have highlighted an inflammatory  
87 cytokine storm and lymphocytopenia as common features relating to disease severity (4–6). It  
88 has also been suggested that the presenting cytokine storm is related to rapid disease  
89 progression or inadequate response to treatment (6). Thus, it is vitally essential to tease out  
90 which peripheral markers are reliably related to disease severity to administer treatment at the  
91 earliest stage.

92

93 Furthermore, central nervous system (CNS) involvement has also been reported in hospitalized  
94 patients infected with SARS (7). It is plausible that patients suffering from COVID-19 might  
95 also exhibit CNS damage. Our previous results show neurochemical evidence of neuronal  
96 injury and glial response in patients with severe and critical COVID-19 and are associated with  
97 disease severity (8). Therefore, it is plausible that other CNS injury markers can be detected in  
98 the blood to support the possible impact of COVID-19 on the CNS. In this study, by examining

99 an extensive collection of inflammatory, immune response, cardiovascular and neurological  
100 markers in the blood, we hope to highlight biomarkers, which demonstrate the progression  
101 from mild to critical disease.

102

## 103 **Results**

### 104 **Cohort demographics**

105 An overview of the patient demographics is provided in Table 1 and significance testing of age,  
106 gender and “*days since symptom onset*” between groups is provided in Supplementary Table  
107 1. The mild group was identified to contain patients significantly younger when compared to  
108 the remaining groups (control p-value = 0.01, severe p-value = 0.02 and critical p-value = 0.01).  
109 No significant difference in age was identified between the remainder of the groups, including  
110 between the control group and the case group (p-value = 0.15).

111 Gender was identified to be significantly different between the control and the critical group  
112 (p-value = 0.005) and between the mild and the critical group (p-value = 0.002) only. There  
113 was no significant difference in gender distribution between the control group and the case  
114 group (p-value = 0.16). The number “*days since symptom onset*” was found to be significantly  
115 higher in the mild group when compared to the severe (p-value 5.41e-05) and critical group (p-  
116 value = 1.60e-05), with no difference between the severe and the critical group (p-value =  
117 0.434).

118 *Table 1: Cohort demographics*

	Control	Mild	Severe	Critical	Total cases	
Participants (n)	28	26	9	24	59	
Follow-up (n)	0	6	0	5	11	
Gender (M/F)	15/13	13/13	6/3	22/2	41/18	
Age (95% CI)	63.1 (55.9-70.3)	51.3 (45.9 - 56.8)	64.8 (55.0 - 74.6)	61.0 (56.2-65.8)	57.8 (53.8 – 60.8)	
Ethnicity (n)	African black	NA	0	0	1	1

	Caucasian	NA	20	8	23	51
	Persian	NA	6	1	0	7
	“Days since symptom onset” (95% CI)	NA	20.9 (17.3 - 24.5)	12 (10.3 - 13.7)	11 (9.1-13)	15.5 (13.4-17.7)

119 *The table provides a summary of the available demographics in this study. Cases represent the*  
 120 *mild, the severe, and the critical group merged into one group. The “Follow-up” represents*  
 121 *the number of patients that had samples taken at two different time points. The mild group was*  
 122 *identified to contain patients significantly younger when compared to the remaining groups*  
 123 *(control p-value = 0.01, severe p-value = 0.02 and the critical p-value = 0.01). Gender was*  
 124 *identified to be significantly different between the control and the critical group (p-value =*  
 125 *0.005) and between the mild and the critical group (p-value = 0.002) only. The number of*  
 126 *“days since symptom onset” was found to be significantly higher in the mild group when*  
 127 *compared to the severe (p-value = 5.41e-05) and the critical group (p-value = 1.60e-05).*  
 128 *Ethnicity information was unavailable for the control group. Abbreviations: M = Males, F =*  
 129 *Females, CI = Confidence Interval.*

130

### 131 **Summary of OLINK data processing**

132 The OLINK cardiovascular, immune, inflammation and neurology panels consisted of 92  
 133 proteins each. Protein profiling the 87 samples resulted in the measurement of 368 proteins per  
 134 sample. One sample, belonging to the mild symptom group, failed in two assays (immune and  
 135 neurology) and was excluded from the failed panels, but were retained for analysis involving  
 136 the cardiovascular and inflammation panels.

137 Thirteen proteins had missing Normalized Protein eXpression (NPX) values or had NPX values  
 138 below the protein-specific limit of detection (LOD) in more than 50% of samples in all four  
 139 disease groups. These 13 proteins were removed, leaving 355 proteins, of which 344 proteins  
 140 were unique due to protein duplication across the four panels.

141

### 142 **Summary of differential expression analysis**

143 A summary of the number of proteins being significantly perturbed in each analysis is provided  
 144 in Table 2. The complete differential expression (DE) results for all analyses are available in  
 145 Supplementary Table 2 and can also be explored using the data explorer application developed  
 146 in this study (<https://phidatalab-shiny.rosalind.kcl.ac.uk/COVID19/>).

147 *Table 2: Summary of differential expression analysis*


Analysis	Total DE	Up	Down	Most sig	logFC	FDR p-value
control vs mild	147	42	105	NF2	- 4.62E+00	2.57E-42
control vs severe	65	8	57	MANF	- 4.71E+00	5.12E-16
control vs critical	187	82	105	NF2	- 4.44E+00	2.40E-36
mild vs severe	146	97	49	EN- RAGE	2.16E+00	5.33E-09
mild vs critical	197	158	39	CTSL1	2.16E+00	3.76E-13
severe vs critical	64	63	1	IL-18R1	5.79E-01	0.00139
control vs case	269	120	149	NF2	- 4.62E+00	1.31E-86
mild group longitudinal	13	10	3	BOC	1.57E+00	0.001243
critical group longitudinal	6	3	3	DECR1	0.6896971	0.023089

148 *The table provides a summary of the number of significantly (FDR p-value  $\leq 0.05$ ) differentially*  
 149 *expressed proteins identified in all nine analyses. “Total DE” is the total number of*  
 150 *differentially expressed proteins identified in the analysis, “Up” represents the number of*  
 151 *proteins that are up-regulated and “Down” represents the number of down-regulated proteins.*  
 152 *“Most sig” represents the most significant perturbed protein in the analysis and is provided as*  
 153 *the protein symbol. Abbreviations: logFC = log fold change, FDR = false discovery rate.*

154

### 155 **Proteins differentially expressed in COVID-19**

156 The “control vs case” analysis identified 269 proteins as significantly differentially expressed  
 157 in COVID-19 patients, with the NF2 protein identified as the most perturbed (FDR p-value =  
 158 1.31E-86, logFC = -4.62E+00). The NF2 protein was also identified as the most perturbed  
 159 protein in multiple analyses (“control vs mild”, “control vs critical” and “control vs case”) and  
 160 was the single most perturbed protein from all nine analyses. The expression pattern of the NF2  
 161 protein per sample is illustrated in Figure 1.



162

163 *Figure 1: NF2 Expression across all disease groups. This protein was identified as the most*  
164 *perturbed protein in the “control vs case” analysis and is significantly down-regulated in all*  
165 *COVID-19 patients, regardless of infection severity.*

166


167 The 269 proteins perturbed in COVID-19 mapped to 265 unique Entrez gene IDs in the  
168 ConsensusPathDB database, which identified 285 significantly enriched biological pathways.

169 The most significantly enriched pathway was the “Cytokine-cytokine receptor interaction”

170 (FDR adjusted p-value = 1.72 e-41). The pathway, along with the enriched proteins, is



171 illustrated in Figure 1Figure 2. The complete pathway enrichment analysis results are provided  
 172 in Supplementary Table 3



173  
 174 *Figure 2: Cytokine-cytokine receptor interaction. The 269 proteins significantly differentially*  
 175 *expressed in COVID-19 patients were significantly enriched in the “cytokine-cytokine receptor*  
 176 *interaction” pathway, which is illustrated above. The proteins highlighted in green are up-*  
 177 *regulated, and the proteins highlighted in red were down-regulated in COVID-19. The figure*  
 178 *was generated using the “KEGG mapper – Search&Color Pathway” (Kanehisa & Sato, 2020).*


179  
 180 **Proteins associated with COVID-19 severity**

181 Eleven proteins were identified to be significantly differentially expressed between the control,  
 182 the mild, the severe and the critical symptom groups. Eight of these proteins were consistently  
 183 perturbed in the same direction as the infection symptoms increased (control -> mild -> severe  
 184 -> critical). Due to the presence of the duplicate proteins across the different panels, these eight  
 185 proteins correspond to six unique proteins. The six proteins are IL6, CKAP4, Gal-9, IL-1ra,  
 186 LILRB4 and PD-L1, and are deemed to be associated with COVID-19 severity. None of these

187 proteins originates from the neurology panel and their statistical significance across the nine  
188 analyses is included in Supplementary Table 2.

189 The IL6 protein was discovered to have been repeated on three different panels, and its  
190 expression pattern and significance level were found to be very similar between the disease  
191 groups. When comparing the overall magnitude of expression change from the control group  
192 to the critical group (“control vs critical” analysis), IL6 protein on the immune, inflammation  
193 and the cardiovascular panel has a logFC of 4.23, 4.49, 4.79, and an FDR p-value of 4.01e-10,  
194 2.74e-10 and 2.61e-10, respectively. The consistency in results provides validity across the  
195 different panels and demonstrates that IL6 protein is reliably detected as significantly increased  
196 in COVID-19.

197 The expression of all six proteins was observed to significantly increase from the control group  
198 to the mild group, which then further increases in the severe group, and increases even further  
199 in the critical group. Their expression patterns for these proteins is shown in Figure 3: Six  
200 proteins a) IL6, b) PD-L1, c) CKAP4, d) IL-1ra e) Gal-9 and f) LILRB4 are consistently  
201 differentially expressed between the control, the mild, the severe and the critical symptom  
202 groups after controlling for age, gender, and “days since symptom onset”, suggesting these  
203 proteins may be associated with disease severity. . The proteins can be ranked by their  
204 magnitude of fold change from the control group to the critical group (as determined from  
205 the “control vs critical” analysis) as follows; IL6 (logFC=4.79), IL-1ra (logFC=2.43), CKAP4  
206 (logFC=1.98), LILRB4 (logFC=1.79), Gal-9 (logFC=1.60), PD-L1 (logFC=1.25). Pathway  
207 analysis identified all six proteins as significantly enriched in the “Immune system” (FDR  
208 adjusted p-value = 1e-4).



209

210 *Figure 3: Six proteins a) IL6, b) PD-L1, c) CKAP4, d) IL-1ra e) Gal-9 and f) LILRB4 are*  
211 *consistently differentially expressed between the control, the mild, the severe and the critical*  
212 *symptom groups after controlling for age, gender, and “days since symptom onset”, suggesting*  
213 *these proteins may be associated with disease severity.*

214

### 215 **Longitudinal data analysis**

216 The mild symptom group (six patients) and the critical symptom group (five patients) consisted  
217 of patients where blood samples were taken at two different time points after the onset of  
218 disease symptoms. A summary of the demographics of these longitudinal samples is provided  
219 in Table 3: Demographics of the longitudinal samples. A summary of the number of proteins  
220 perturbed in each longitudinal analysis is included in Table 2, and the complete DE analysis  
221 results from these analyses are included in Supplementary Table 2. No protein was identified  
222 to be significantly perturbed in both the “mild group longitudinal” and the “critical group  
223 longitudinal” analyses.

224 *Table 3: Demographics of the longitudinal samples*

		Mild	Critical
No. patients		6	5
Gender (M/F)		3/3	5/0
Age (95% CI)		51.5 (36.8 - 66.2)	55.6 (45.8 - 73.4)
Ethnicity	Caucasian	4	5
	Persian	2	0
Baseline sample symptom duration (95% CI)		8.5 (3.4-13.6)	8.4 (5.5 - 11.3)
Repeat sample symptom duration (95% CI)		24.7 (22.2 - 27.1)	11.2 (7.33 - 15.1)
Average time between samples (95% CI)		16.2 (12.1 - 20.2)	2.8 (1.4 - 4.2)

225 *The table provides the demographics of the longitudinal samples in this study. Abbreviations:*  
 226 *M = Males, F = Females, CI = Confidence Interval.*

227

### 228 **OLINK neuronal proteins correlated with markers of neural injury and astrogliosis**

229 The three proteins measured on the Simoa platform were absent from the OLINK platform.

230 The three proteins tau, NfL and GFAP were significantly ( $p\text{-value} \leq 0.05$ ) correlated with 97,  
 231 233, 165 proteins from the OLINK platform, respectively (Supplementary Table 4), of which  
 232 20, 61 and 41 proteins belong to the Neurology panel, respectively.

233 NfL was identified to be most correlated with EDA2R ( $r=0.66$ ,  $p\text{-value}=4.01e-12$ ), which is  
 234 not significantly perturbed in any of the nine DE analysis performed in this study (see Figure  
 235 4a). Tau and GFAP were identified to be both most correlated with SCARB2 (tau:  $r=0.39$  and  
 236  $p\text{-value}=1.74e-4$ , GFAP:  $r=0.46$ ,  $p\text{-value}=6.47e-6$ ). When compared to controls, SCARB2 is  
 237 significantly up-regulated in the mild ( $\log\text{FC}=0.59$ ,  $p\text{-value}=4.7e-3$ ) and critical groups  
 238 ( $\log\text{FC}=0.72$ ,  $p\text{-value}=0.01$ ) but not in the severe group ( $\log\text{FC}=1.02$ ,  $p\text{-value}=0.12$ ). Although  
 239 SCARB2 is not statistically associated with disease severity, the expression of this protein is  
 240 noted to increase inline with disease severity (Figure 4b).


241 In addition, biomarkers of disease severity (Figure 3) were vastly more associated with NfL  
 242 (CKAP4,  $r=0.642$ ; PD-L1,  $r=0.623$ ; IL6,  $r=0.528$ ; Gal-9, LILRB4,  $r=0.508$ ;  $r=0.486$ ; IL-1ra,

243  $r=0.435$ ) than GFAP or tau indicating that disease severity includes increased CNS damage as  
244 marked by NfL and not GFAP and tau.

245

#### 246 **Differentially expressed OLINK neuronal proteins**

247 From the “control vs case” analysis, 71 proteins on the neurology panel were identified to be  
248 perturbed in COVID-19, with LAT (see Figure 4c) identified to be the most perturbed in this  
249 analysis ( $\log_{2}FC=-3.9$ ,  $p\text{-value}=4.46e-22$ ). LAT is also significantly differentially expressed  
250 between the mild and severe group ( $\log_{2}FC=1.94$ ,  $p\text{-value}=7.7e-3$ ), but not between the severe  
251 and critical group ( $\log_{2}FC=-0.08$ ,  $p\text{-value}=0.89$ ). This suggests LAT is down-regulated in  
252 COVID-19 but is not associated with disease severity. From all analyses involving the neuronal  
253 panel, MANF (see Figure 4d) was the most perturbed protein, and is significantly down-  
254 regulated in the mild ( $\log_{2}FC= -2.85$ ,  $p\text{-value}= 2.53e-28$ ), severe ( $\log_{2}FC=-4.71$ ,  $p\text{-value}=8.58e-17$ )  
255 and critical symptom groups ( $\log_{2}FC=-1.81$ ,  $p\text{-value}=5.98e-17$ ). However, MANF is not  
256 significantly perturbed between the mild and severe group ( $\log_{2}FC=0.8$ ,  $p\text{-value}=0.3$ ), or the  
257 severe and critical group ( $\log_{2}FC=0.3$ ,  $p\text{-value}=0.61$ ). This suggests MANF is down-regulated  
258 in COVID-19 and is not associated with disease severity.



259

260 *Figure 4: Expression patterns of the neuronal proteins perturbed in COVID-19. A) EDA2R is*  
261 *correlated with the Simoa measured NfL. B) SCARB2 is correlated with the Simoa measured*  
262 *tau and GFAP. C) LAT is most differentially expressed protein in the “control vs case”*  
263 *analysis. D) MANF is the most differentially expressed neuronal protein in this study from all*  
264 *analyses performed in this study. Statistical analysis was performed while controlling for age,*  
265 *gender, and “days since symptom onset.”*

266

## 267 Discussion

268 This study explored the changes in protein expression between four disease groups where  
269 patients were either controls (tested negative for COVID-19 using PCR) or had mild, severe or  
270 critical symptoms of COVID-19. In addition, longitudinal data were available where patients

271 had blood drawn at two different time points after the onset of disease symptoms. In total nine  
272 DE analysis were performed ("control vs mild", "control vs severe", "control vs critical", "mild  
273 vs severe", "mild vs critical", "severe vs critical", "control vs case", "mild group longitudinal"  
274 and "critical group longitudinal") to identify proteins significantly perturbed between various  
275 disease groups and within groups across time. Furthermore, the results have been made readily  
276 available in an interactive web-based R Shiny application ([https://phidatalab-  
277 shiny.rosalind.kcl.ac.uk/COVID19/](https://phidatalab-shiny.rosalind.kcl.ac.uk/COVID19/)), allowing researchers to swiftly visualize and further  
278 investigate the expression changes of specific proteins in COVID-19 patients.

279

### 280 **Biomarkers for COVID-19 infection**

281 The three different symptom severity groups (mild, severe and critical) were merged to create  
282 a “case” group and were compared to the control group to identify common differentially  
283 expressed proteins in COVID-19. A total of 269 proteins were identified to be significantly  
284 differentially expressed, of which 120 are up-regulated, and 149 are down-regulated in  
285 COVID-19 cases. Notably, over 75% of proteins measured in this study are significantly  
286 perturbed in COVID-19 cases as compared to COVID-19 negative controls of similar age  
287 groups. Neurofibromin 2 (NF2) was identified as the most perturbed protein in this study and  
288 regardless of disease severity, was significantly down-regulated in all COVID-19 patients  
289 (Figure 1). This protein was not perturbed according to the longitudinal analysis, and therefore,  
290 is not regarded to be associated with the duration of disease. The NF2 protein, or better known  
291 as the Merlin protein (moesin-ezrin-radixin-like protein), functions as a tumour suppressor  
292 through impacting mechanisms related to proliferation, apoptosis, survival, motility, adhesion,  
293 and invasion (9,10). The Merlin protein also activates anti-mitogenic signalling at tight-  
294 junctions; hence, an inactivation of Merlin causes uncontrolled mitogenic signalling and  
295 tumorigenesis (11).

296

### 297 **Biomarkers for infection severity**

298 Six proteins (IL6, CKAP4, Gal-9, IL-1ra, LILRB4 and PD-L1) were consistently differentially  
299 expressed between the control, mild, severe and critical symptom groups. The expression of all  
300 six proteins increased as the severity of the symptoms increased, suggesting these proteins may  
301 be a useful tool in monitoring the progression from mild to critical disease. Furthermore, these  
302 six proteins are not significantly perturbed within the longitudinal analysis, suggesting these  
303 proteins are not associated with the length of the duration of infection.

304 Interleukin 6 (IL6) is an inflammatory cytokine that is an endogenous pyrogen of inducing  
305 fever in patients with autoimmune diseases or infections. IL6 is an acute phase inflammatory  
306 cytokine that has been suggested to reflect the inflammatory state of the lungs. Elevated IL6  
307 levels have been discovered in ARDS and lung transplantation complications (4,12), and has  
308 already been shown to be elevated in COVID-19 patients (12–14). Furthermore, it has also  
309 been suggested to be associated with increased COVID-19 mortality (15). Our results add  
310 strong support that IL-6 expression increases with disease severity.

311 Furthermore, while not assessed in this study, IL6 does show some evidence of decreasing in  
312 disease remission in COVID-19 patients (12,16) and is, therefore, a viable target for treating  
313 the cytokine storm during disease progression. Tocilizumab is a monoclonal antibody targeted  
314 against IL6 and its receptor (IL6R) inhibitor that is commonly used to treat inflammatory and  
315 autoimmune conditions (17). It is currently being investigated in its effectiveness to treat  
316 COVID-19 patients (18,19).

317 In addition to IL6, we have highlighted novel protein markers associated with disease severity  
318 in COVID-19 patients and are all involved in the immune system, with many mediating  
319 cytokine productions, including IL6. Cytoskeleton Associated Protein 4 (CKAP4) is involved  
320 in the innate immune system and mediates the anchoring of endoplasmic reticulum to



321 microtubules (20). A recent study identified that serum CKAP4 levels of lung cancer patients  
322 were significantly higher than those of healthy controls, suggesting CKAP4 as a potential early  
323 biomarker for lung cancer (21). Galectin 9 (Gal-9) belongs to a family of beta-galactoside-  
324 binding proteins that are implicated in modulating cell-cell and cell-matrix interactions and has  
325 a diverse role in the innate and adaptive immune system [provided by RefSeq, Jul 2008]. Gal-  
326 9 has been demonstrated to activate ERL/2 phosphorylation, inducing chemokine and cytokine  
327 production, including IL-6 (22,23). Serum Gal-9 concentrations have been observed to be  
328 significantly increased in patients with infections such as HIV (24), hepatitis C virus (HCV)  
329 (25) and malaria (26), suggesting increased gal-9 production is not specific to COVID-19  
330 infection. Interleukin-1 receptor antagonist protein (IL-1ra) inhibits the activities of interleukin  
331 1 alpha (IL1A) and interleukin 1 beta (IL1B) and modulates a variety of interleukin 1 related  
332 immune and inflammatory responses [provided by RefSeq, Jan 2016]. Essentially, IL-1ra is an  
333 inflammation-inhibitor protein that has also been identified to be significantly higher in  
334 COVID-19 patients with a severe symptom (27). Anakinra is a recombinant IL-1ra that has  
335 already been administered to COVID-19 patients with suggested improved clinical outcome in  
336 two small uncontrolled studies (28,29). Randomized controlled studies are still ongoing.

337 Leukocyte Immunoglobulin Like Receptor B4 (LILRB4) protein belongs to a family of cell  
338 surface receptors that have been suggested to down-regulate the immune response by Inhibiting  
339 monocyte activation and inhibiting the production of a critical pro-inflammatory cytokine  
340 (TNF $\alpha$ ) (30). Increased expression of LILRB4 was associated with increased disease severity  
341 in this study, suggesting a possible decrease in monocyte activation leading to an immune-  
342 suppressive microenvironment. LILRB4 represents a compelling target to investigate COVID-  
343 19 treatment. Programmed cell death 1 ligand 1 (PD-L1) is a type 1 transmembrane protein  
344 that has immunoglobulin domains which bind to receptors commonly found on T-cells to  
345 inhibit T-cell activation and cytokine production. During infection or inflammation of healthy

346 tissue, this interaction is essential for preventing autoimmunity by maintaining homeostasis of  
347 the immune response [provided by RefSeq, Sep 2015]. PD-L1 is found in higher concentrations  
348 on some types of cancer cells than healthy cells, which, when bound to PD-1 on T-cells,  
349 prevents the T cell from killing the PD-L1 containing cancer cell. To address this, immune  
350 checkpoint inhibitors (ICIs) are commonly used in various cancers to block PD-L1 on the  
351 cancer cell binding to the T cell, reinvigorating antitumor immune responses (31). However,  
352 this immunodeficiency in cancer patients may be the primary cause of why they represent a  
353 vulnerable population in the COVID-19 pandemic (32). As these novel proteins are not  
354 associated with the duration of infection in neither the mild nor the severe group, they may  
355 hold potential as biomarkers for disease severity. However, as members of the immune system,  
356 it is unknown if these proteins are markers of general infection rather than COVID-19, thus;  
357 they require further investigation for disease specificity, but together, may still be valuable as  
358 an additional biomarker for COVID-19 severity after disease confirmation.

359

### 360 **Biomarkers for infection duration**

361 In this study, six patients from the mild group and five patients from the critical group were  
362 sampled at two different time-points to identify biomarkers for disease duration. This identified  
363 thirteen (BOC, KYNU, SPRY2, KIM1, SCF, MANF, SLAMF1, CD84, SCF, PADI2, PAPP, A,  
364 CLEC4A, TANK) and six (DECR1, TPSAB1, TF, GDF-8, GZMA, BCAN) proteins in the  
365 mild and the critical group respectively, where proteins expression significantly changed from  
366 the baseline sample to the first repeat. No protein was discovered to be significantly perturbed  
367 in both groups over time; therefore, these biomarkers may be specific within their respective  
368 symptom severity groups. However, it is essential to note that sampling time between the  
369 baseline and repeat sample differed between the two severity groups, with the mild group  
370 averaging 16.2 days and the critical group patients averaging only 2.8 days. The smaller

371 number of days between repeat sampling in the critical symptom group may have been  
372 inadequate to measure significant changes in protein expression that reflect infection duration.

373

#### 374 **CNS injury biomarkers**

375 We have previously shown neurochemical evidence of neuronal injury and glial response in  
376 patients with severe and critical COVID-19. The results of this study indicate that astrocytic  
377 activation and/or injury (GFAP) may be a common feature in mild and severe stages of  
378 COVID-19, while neuronal injury (NfL) occurs later in the disease process and mainly in  
379 patients with critical symptoms (8). In this current study, we expanded our proteomic profiling  
380 of CNS proteins, on the same patients, by using the OLINK neurology panel. Correlation  
381 analysis identified SCARB2 is most correlated with both tau and GFAP, and EDA2R is most  
382 correlated with Nfl, suggesting that these novel proteins are associated with COVID-19-related  
383 early or later CNS injury, respectively. Furthermore, MANF and LAT were significantly down-  
384 regulated in COVID-19 cases as compared to controls, with expression patterns suggesting it  
385 is not associated with disease severity. Although MANF and LAT were present on the OLINK  
386 neuronal panel, both proteins are not specific to the brain. Mesencephalic Astrocyte Derived  
387 Neurotrophic Factor (MANF) is an endoplasmic reticulum (ER) stress protein and has been  
388 suggested to have neuroprotective effects against cerebral ischemia (33). Linker For Activation  
389 Of T Cells (LAT) protein is primarily expressed in T-cells and is required for T-cell antigen  
390 receptor (TCR) and pre-TCR-mediated signalling. It is important to note that our putative  
391 biomarkers of disease progression in COVID-19 (IL6, CKAP4, Gal-9, IL-1ra, LILRB4 and  
392 PD-L1) were associated to NfL but to a much lesser extent to GFAP and tau.

393 The CNS involvement in COVID-19 is not known, and direct invasion of the virus may be  
394 unlikely. Support for a hypothesis of CNS infection through a nasopharyngeal route is provided  
395 by clinical observations of frequent and persistent anosmia dysgeusia (16). Neurological

396 symptoms are reported in severe cases, supporting the concept that CNS symptoms might be  
397 secondary to severe respiratory failure (34). CNS hypoxia from respiratory failure caused by  
398 COVID-19, thrombotic microangiopathy, or an indirect effect of extensive cytokine activation  
399 that is commonly found in severe COVID-19 is more probable explanations of these increases  
400 (Kanberg et al., 2020). Thus, this explorative study of the neurology-associated proteins in the  
401 blood may add further insight into hypoxia biomarkers in a broader sense, e.g., to monitor  
402 cardiac arrest. Furthermore, the evidence that specific CNS proteins are detectable in blood, as  
403 shown by this study, may open up avenues of investigation in CNS injury for  
404 neurodegenerative disorders, multiple sclerosis or HIV, where GFAP and NfL are regularly  
405 investigated.

406

#### 407 **Limitations**

408 Due to blood samples being taken as part of a routine hospital procedure during an  
409 unprecedented time, this study was restricted to a small cohort, certain aspects of this study  
410 design were uncontrollable and valuable information was unobtainable. The number of “days  
411 since symptom onset”, was identified to be significantly higher in the mild symptom group  
412 when compared to the severe and the critical symptom group. Essentially, following the onset  
413 of symptoms, samples were drawn from the mild symptom group at a much later date when  
414 compared to the severe and the critical symptom group. As a result, expression changes  
415 involving the mild group (“mild vs severe” and “mild vs critical”) may reflect the duration a  
416 patient has been infected with COVID-19 rather than being a reflection of symptom severity.  
417 However, as the longitudinal analysis in this study measures protein expression changes during  
418 infection, these results were used to differentiate between expression changes likely due to  
419 disease severity and duration of infection.

420 Furthermore, information on comorbidities, medical history and medications are unknown.  
421 Hospitalized patients with COVID-19 are known to be more likely to have an underlying health  
422 disorder such as hypertension, obesity and diabetes (35), and it is unknown if this cohort has  
423 the same characteristics. Moreover, it is unknown if any medication, in addition to oxygen  
424 supplementation, was administered to COVID-19 patients, therefore; protein expression  
425 changes in this study may be a reflection of a combination of COVID-19, comorbidity and  
426 medication.

427

## 428 **Conclusion**

429 This extensive proteomic analysis unbiasedly identified IL6 and five novel proteins (CKAP4,  
430 Gal-9, IL-1ra, LILRB4 and PD-L1) to be associated with disease severity in COVID-19 cases.  
431 Elevated levels of proteins significantly increased as the disease symptom severity deteriorated  
432 and highlight a shared mechanism of cytokine-mediated lung injury cause by viral injection.  
433 These proteins warrant further investigation but could provide potential as early biomarkers for  
434 disease severity and may serve as potential therapeutic targets, or as biomarkers to monitor the  
435 effect of treatments to modulate the immune system and/or suppress the infection. Overall, the  
436 results of this study further increase the understanding of COVID-19, which includes CNS  
437 involvement, and have been made widely available to researchers as an interactive web-based  
438 tool accessible at <https://phidatalab-shiny.rosalind.kcl.ac.uk/COVID19/>.

439

## 440 **Materials and Methods**

### 441 **Cohort**

442 Fifty-nine patients with confirmed COVID-19 and 28 healthy, age-matched controls were  
443 included. Samples were collected at diagnosis and repeated when possible. Patients were  
444 divided into three groups related to systemic disease severity: 26 patients with mild (i.e., not  
445 requiring hospitalization) 9 with severe (hospitalized and requiring oxygen supplementation),  
446 and 24 with critical disease (admitted to intensive care unit [ICU] and placed on mechanical  
447 ventilation [n=23] or not considered a candidate for ICU treatment and with fatal outcome  
448 [n=1]). The controls were initially recruited as cognitively unimpaired controls for an  
449 observational dementia study, and they were all neurologically and psychiatrically normal with  
450 any magnetic resonance imaging (MRI) abnormalities set as an exclusion criteria. Follow-up  
451 samples on patients with critical COVID-19 were collected when they were still in ICU.

452

### 453 **COVID-19 confirmation**

454 The diagnosis was confirmed using real-time polymerase chain reaction (rtPCR) analysis of  
455 nasal and throat swab specimens. Nucleic acid was extracted from clinical samples in a MagNA  
456 Pure 96 instrument using the Total Nucleic Acid isolation kit (Roche). rtPCR targeting the  
457 RdRP region was performed in a QuantStudio 6 instrument (Applied Biosystems, Foster City,  
458 CA) using the probe described by Corman et al. and the primers RdRP\_Fi,  
459 GTCATGTGTGGCGGTTCACT and RdRP\_Ri, CAACACTATTAGCATAAGCAGTTGT  
460 (36).

461

### 462 **Plasma proteomics**

463 Plasma glial fibrillary acidic protein (GFAP), neurofilament light (NfL), and tau were  
464 measured and reported in our recent COVID-19 related study (8), which discovered

465 neurochemical evidence to support the possible impact of COVID-19 on the CNS. The Simoa  
466 protein measurements are detailed in (8). Plasma from the same participants was also used for  
467 the OLINK protein profiling for this study. Protein concentrations were measured on the Olink  
468 Multiplex platform (Olink Proteomics AB, Uppsala, Sweden) using the cardiovascular II  
469 (v.5006), immune response (v.3203), inflammation (v.3022) and neurology (v.8012) 96-plex  
470 panels. The OLINK immunoassays are based on the Proximity Extension Assay (PEA)  
471 technology (37), which uses a pair of oligonucleotide-labelled antibodies to bind to their  
472 respective target protein. When the two antibodies are in close proximity, a new polymerase  
473 chain reaction target sequence is formed, which is then detected and quantified by quantitative  
474 real-time PCR.

475

#### 476 **Statistical analysis**

477 The Olink-generated data was preprocessed and quality controlled using the platform-specific  
478 “Olink NPX manager” software, which background corrects, log<sub>2</sub> transforms and normalizes  
479 all samples to an arbitrary NPX scale. The NPX is a relative quantification unit where a  
480 difference of 1 NPX equates to a doubling of protein concentration.

481 Additional data processing was performed in RStudio (version 1.2.1335) using R (version  
482 3.6.0). First, samples with a failure rate of more than 50% across all proteins were removed.  
483 Next, proteins were removed if the protein failed to quantify in more than 50% of samples in  
484 each disease group, or if the protein NPX value fell below the protein-specific LOD value in  
485 more than 50% of samples in each disease group. The remaining NPX values below the LOD  
486 were substituted by the proteins  $\text{LOD}/\sqrt{2}$ .

487 The demographic variables available were ethnicity, age, gender and “days since symptom  
488 onset”. The “days since symptom onset” variable represents the number of days that a blood

489 sample was taken after the first self-reported symptom date. The Welch Two Sample t-test and  
490 the Fisher's exact test was performed where appropriate to identify any significant differences  
491 in age, gender and "days since symptom onset" between groups.

492 DE analysis was performed using the R package "limma" (version 3.42.2) using gender, age  
493 and "days since symptom onset" as covariates where possible. A protein was determined to be  
494 significantly differentially expressed if the false discovery rate (FDR) adjusted p-value was  $\leq$   
495 0.05. The following self-explanatory comparisons were made: 1) "control vs mild", 2) "control  
496 vs severe", 3) "control vs critical", 4) "mild vs severe", 5) "mild vs critical", 6) "severe vs  
497 critical", 7) "control vs case" (where patients with mild, severe and critical symptoms are  
498 merged and treated as the cases).

499 Some patients within the mild and the severe symptom group had protein concentrations  
500 measured at two different time points; therefore, two additional DE analysis was performed  
501 independently in the mild and the severe symptom groups and are referred to as 1) "mild group  
502 longitudinal" and 2) "critical group longitudinal" analysis, respectively. The two longitudinal  
503 analyses were performed in their respective disease groups using a paired t-test approach in  
504 limma.

505 Pathway enrichment analysis was performed using an Over-Representation Analysis (ORA)  
506 implemented through the ConsensusPathDB (<http://cpdb.molgen.mpg.de>) web-based platform  
507 (version 34) (38). Significant results were then explored using the "KEGG mapper –  
508 Search&Color Pathway" to map and visualize proteins in a specific biological pathway (39).

509 This study further explores CNS injury-related biomarkers in COVID-19 by correlating the  
510 Simoa measured proteins with the OLINK measured proteins using Pearson's correlation.

511



## 512 **Data availability**

513 The proteomic data is available in the BioStudies database (<http://www.ebi.ac.uk/biostudies>)  
514 under accession number S-BSST416. Additionally, an R shiny application was written in R  
515 using the “shiny” framework (version 1.4.0.2) to allow the quick and efficient visualization of  
516 the expression of specific proteins across the control, mild, severe and severe symptom groups.  
517 The application is hosted on the research computing facility at King’s College London  
518 (Rosalind), and allows researchers to quickly visualize and investigate the results across all  
519 nine DE analyses performed in this study. The application can be accessed at [https://phidatalab-](https://phidatalab-shiny.rosalind.kcl.ac.uk/COVID19/)  
520 [shiny.rosalind.kcl.ac.uk/COVID19/](https://phidatalab-shiny.rosalind.kcl.ac.uk/COVID19/). All data analysis scripts used in this study have been  
521 deposited in zenodo under the DOI: 10.5281/zenodo.3895886

## 522 **Ethics Statement**

523 This study has been approved by the Swedish Ethical Review Authority (2020-01771). All  
524 participants provided written informed consent, in those with severe COVID-19, this was  
525 obtained before they were placed on mechanical ventilation and were deemed fully capable  
526 of understanding the nature of the study and their part in.

## 527 **Acknowledgements**

528 This study presents independent research supported by the NIHR BioResource Centre  
529 Maudsley at South London and Maudsley NHS Foundation Trust (SLaM) & Institute of  
530 Psychiatry, Psychology and Neuroscience (IoPPN), King’s College London. The views  
531 expressed are those of the author(s) and not necessarily those of the NHS, NIHR, Department  
532 of Health or King’s College London. The authors acknowledge use of the research computing  
533 facility at King’s College London, Rosalind (<https://rosalind.kcl.ac.uk>), which is delivered in  
534 partnership with the National Institute for Health Research (NIHR) Biomedical Research  
535 Centres at South London & Maudsley and Guy’s & St. Thomas’ NHS Foundation Trusts, and  
536 part-funded by capital equipment grants from the Maudsley Charity (award 980) and Guy’s &

537 St. Thomas' Charity (TR130505). The views expressed are those of the author(s) and not  
538 necessarily those of the NHS, the NIHR, King's College London, or the Department of Health  
539 and Social Care.

540

541 NJA is supported by the Wallenberg Centre for Molecular and Translational Medicine, the  
542 Swedish Alzheimer Foundation (Alzheimerfonden), the Swedish Dementia Foundation  
543 (Demensförbundet), Hjärnfonden, Sweden and the Anna Lisa and Brother Björnsson's  
544 Foundation. RJBD is supported by 1. Health Data Research UK, which is funded by the UK  
545 Medical Research Council, Engineering and Physical Sciences Research Council, Economic  
546 and Social Research Council, Department of Health and Social Care (England), Chief Scientist  
547 Office of the Scottish Government Health and Social Care Directorates, Health and Social Care  
548 Research and Development Division (Welsh Government), Public Health Agency (Northern  
549 Ireland), British Heart Foundation and Wellcome Trust. 2. The National Institute for Health  
550 Research University College London Hospitals Biomedical Research Centre. KB is supported  
551 by the Swedish Research Council (#2017-00915), the Alzheimer Drug Discovery Foundation  
552 (ADDF), USA (#RDAPB-201809-2016615), the Swedish Alzheimer Foundation (#AF-  
553 742881), Hjärnfonden, Sweden (#FO2017-0243), the Swedish state under the agreement  
554 between the Swedish government and the County Councils, the ALF-agreement (#ALFGBG-  
555 715986), and European Union Joint Program for Neurodegenerative Disorders (JPND2019-  
556 466-236). MG is supported by The Swedish State Support for Clinical Research (ALFGBG-  
557 717531) and by SciLifeLab/KAW national COVID-19 research program project grant (V-  
558 2020-0250). HZ is a Wallenberg Scholar supported by grants from the Swedish Research  
559 Council (#2018-02532), the European Research Council (#681712), Swedish State Support for  
560 Clinical Research (#ALFGBG-720931), the Alzheimer Drug Discovery Foundation (ADDF),  
561 USA (#201809-2016862), and the UK Dementia Research Institute at UCL.

562 **Conflicts of interest**

563 KB has served as a consultant, at advisory boards, or at data monitoring committees for Abcam,  
564 Axon, Biogen, Julius Clinical, Lilly, MagQu, Novartis, Roche Diagnostics, and Siemens  
565 Healthineers, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS),  
566 which is a part of the GU Ventures Incubator Program (outside submitted work). HZ has served  
567 at scientific advisory boards for Denali, Roche Diagnostics, Wave, Samumed, Siemens  
568 Healthineers, Pinteon Therapeutics and CogRx, has given lectures in symposia sponsored by  
569 Fujirebio, Alzecure and Biogen, and is a co-founder of Brain Biomarker Solutions in  
570 Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside  
571 submitted work).

572

573 **References**

- 574 1. World Health Organization. Coronavirus disease 2019 (COVID-19) Situation Report –  
575 46 [Internet]. 2020 [cited 2020 Jun 8]. Available from:  
576 <https://www.who.int/docs/default-source/coronaviruse/situation-reports/>
- 577 2. Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical characteristics of  
578 coronavirus disease 2019 in China. *N Engl J Med*. 2020 Apr 30;382(18):1708–20.
- 579 3. Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of  
580 critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-  
581 centered, retrospective, observational study. *Lancet Respir Med*. 2020 May  
582 1;8(5):475–81.
- 583 4. Tanaka T, Narazaki M, Kishimoto T. Il-6 in inflammation, Immunity, And disease.  
584 *Cold Spring Harb Perspect Biol*. 2014 Oct 1;6(10).
- 585 5. de Brito R de CCM, Lucena-Silva N, Torres LC, Luna CF, Correia J de B, da Silva  
586 GAP. The balance between the serum levels of IL-6 and IL-10 cytokines discriminates  
587 mild and severe acute pneumonia. *BMC Pulm Med* [Internet]. 2016 Dec 1 [cited 2020  
588 Jun 15];16(1):170. Available from:  
589 <http://bmcpulmed.biomedcentral.com/articles/10.1186/s12890-016-0324-z>
- 590 6. Gupta KK, Khan MA, Singh SK. Constitutive Inflammatory Cytokine Storm: A Major  
591 Threat to Human Health. *J Interf Cytokine Res* [Internet]. 2020 Jan 1 [cited 2020 Jun  
592 15];40(1):19–23. Available from:  
593 <https://www.liebertpub.com/doi/10.1089/jir.2019.0085>
- 594 7. Xu J, Zhong S, Liu J, Li L, Li Y, Wu X, et al. Detection of Severe Acute Respiratory  
595 Syndrome Coronavirus in the Brain: Potential Role of the Chemokine Mig in  
596 Pathogenesis. *Clin Infect Dis*. 2005 Oct 15;41(8):1089–96.

- 597 8. Kanberg N, Ashton NJ, Andersson L-M, Yilmaz A, Lindh M, Nilsson S, et al.  
598 Neurochemical evidence of astrocytic and neuronal injury commonly found in  
599 COVID-19. *Neurology* [Internet]. 2020 Jun 16 [cited 2020 Jun  
600 17];10.1212/WNL.0000000000010111. Available from:  
601 <http://www.neurology.org/lookup/doi/10.1212/WNL.0000000000010111>
- 602 9. Morrow KA, Shevde LA. Merlin: The wizard requires protein stability to function as a  
603 tumor suppressor. Vol. 1826, *Biochimica et Biophysica Acta - Reviews on Cancer*.  
604 NIH Public Access; 2012. p. 400–6.
- 605 10. Shen YC, Arellano-Garcia C, Menjivar RE, Jewett EM, Dohle W, Karchugina S, et al.  
606 Nonsteroidal sulfamate derivatives as new therapeutic approaches for  
607 Neurofibromatosis 2 (NF2). *BMC Pharmacol Toxicol*. 2019 Nov 15;20(1).
- 608 11. Cooper J, Giancotti FG. Molecular insights into NF2/Merlin tumor suppressor  
609 function. Vol. 588, *FEBS Letters*. Elsevier; 2014. p. 2743–52.
- 610 12. Liu T, Zhang J, Yang Y, Ma H, Li Z, Zhang J, et al. The role of interleukin-6 in  
611 monitoring severe case of coronavirus disease 2019. *EMBO Mol Med* [Internet]. 2020  
612 Jun 5 [cited 2020 Jun 15];emmm.202012421. Available from:  
613 <https://onlinelibrary.wiley.com/doi/abs/10.15252/emmm.202012421>
- 614 13. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical  
615 characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a  
616 descriptive study. *Lancet*. 2020 Feb 15;395(10223):507–13.
- 617 14. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to  
618 COVID-19 based on an analysis of data of 150 patients from Wuhan, China. *Intensive*  
619 *Care Medicine*. Springer; 2020. p. 1.

- 620 15. Aziz M, Fatima R, Assaly R. Elevated Interleukin-6 and Severe COVID-19: A Meta-  
621 Analysis. *J Med Virol* [Internet]. 2020 Apr 28 [cited 2020 May 19];jmv.25948.  
622 Available from: <https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.25948>
- 623 16. Pilotto A, Odolini S, Masciocchi S, Comelli A, Volonghi I, Gazzina S, et al. Steroid-  
624 Responsive Encephalitis in Coronavirus Disease 2019. *Ann Neurol* [Internet]. 2020  
625 Jun 9 [cited 2020 Jun 15];ana.25783. Available from:  
626 <https://onlinelibrary.wiley.com/doi/abs/10.1002/ana.25783>
- 627 17. Wishart DS. DrugBank: a comprehensive resource for in silico drug discovery and  
628 exploration. *Nucleic Acids Res*. 2006 Jan 1;34(90001):D668–72.
- 629 18. Zhang X, Song K, Tong F, Fei M, Guo H, Lu Z, et al. First case of COVID-19 in a  
630 patient with multiple myeloma successfully treated with tocilizumab. *Blood Adv*. 2020  
631 Apr 14;4(7):1307–10.
- 632 19. Michot J-M, Albiges L, Chaput N, Saada V, Pommeret F, Griscelli F, et al.  
633 Tocilizumab, an anti-IL6 receptor antibody, to treat Covid-19-related respiratory  
634 failure: a case report. *Ann Oncol*. 2020 Apr;
- 635 20. The UniProt Consortium. UniProt: A worldwide hub of protein knowledge. *Nucleic*  
636 *Acids Res* [Internet]. 2019 [cited 2020 May 19];47(D1):D506–15. Available from:  
637 <https://www.ebi.ac.uk/protins/api/doc/>
- 638 21. Yanagita K, Nagashio R, Jiang SX, Kuchitsu Y, Hachimura K, Ichinoe M, et al.  
639 Cytoskeleton-Associated Protein 4 Is a Novel Serodiagnostic Marker for Lung Cancer.  
640 *Am J Pathol*. 2018 Jun 1;188(6):1328–33.
- 641 22. Dai S-Y, Nakagawa R, Itoh A, Murakami H, Kashio Y, Abe H, et al. Galectin-9  
642 Induces Maturation of Human Monocyte-Derived Dendritic Cells. *J Immunol*. 2005

- 643 Sep 1;175(5):2974–81.
- 644 23. Kojima R, Ohno T, Iikura M, Niki T, Hirashima M, Iwaya K, et al. Galectin-9  
645 Enhances Cytokine Secretion, but Suppresses Survival and Degranulation, in Human  
646 Mast Cell Line. Ryffel B, editor. PLoS One [Internet]. 2014 Jan 20 [cited 2020 May  
647 19];9(1):e86106. Available from: <https://dx.plos.org/10.1371/journal.pone.0086106>
- 648 24. Premeaux TA, D’Antoni ML, Abdel-Mohsen M, Pillai SK, Kallianpur KJ, Nakamoto  
649 BK, et al. Elevated cerebrospinal fluid Galectin-9 is associated with central nervous  
650 system immune activation and poor cognitive performance in older HIV-infected  
651 individuals. J Neurovirol. 2019 Apr 15;25(2):150–61.
- 652 25. Mengshol JA, Golden-Mason L, Arikawa T, Smith M, Niki T, McWilliams R, et al. A  
653 crucial role for Kupffer cell-derived galectin-9 in regulation of T cell immunity in  
654 hepatitis C infection. PLoS One. 2010 Mar 4;5(3).
- 655 26. Dembele BPP, Chagan-Yasutan H, Niki T, Ashino Y, Tangpukdee N, Shinichi E, et al.  
656 Plasma levels of Galectin-9 reflect disease severity in malaria infection. Malar J. 2016  
657 Aug 11;15(1).
- 658 27. Yang Y, Shen C, Li J, Yuan J, Yang M, Wang F, et al. Exuberant elevation of IP-10,  
659 MCP-3 and IL-1ra during SARS-CoV-2 infection is associated with disease severity  
660 and fatal outcome. medRxiv. 2020 Mar 6;2019(December  
661 2019):2020.03.02.20029975.
- 662 28. Franzetti M, Pozzetti U, Carugati M, Pandolfo A, Molteni C, Faccioli P, et al.  
663 Interleukin-1 receptor antagonist anakinra in association with remdesivir in severe  
664 Coronavirus disease 2019: A case report. Int J Infect Dis [Internet]. 2020 May 16  
665 [cited 2020 May 19]; Available from:  
666 <https://linkinghub.elsevier.com/retrieve/pii/S120197122030357X>

- 667 29. Cavalli G, De Luca G, Campochiaro C, Della-Torre E, Ripa M, Canetti D, et al.  
668 Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute  
669 respiratory distress syndrome, and hyperinflammation: a retrospective cohort study.  
670 *Lancet Rheumatol* [Internet]. 2020 [cited 2020 May 19];9913(20):1–7. Available from:  
671 [http://dx.doi.org/10.1016/S2665-9913\(20\)30127-2](http://dx.doi.org/10.1016/S2665-9913(20)30127-2)
- 672 30. Lu HK, Rentero C, Raftery MJ, Borges L, Bryant K, Tedla N. Leukocyte Ig-like  
673 receptor B4 (LILRB4) is a potent inhibitor of Fc $\gamma$ RI-mediated monocyte activation via  
674 dephosphorylation of multiple kinases. *J Biol Chem*. 2009 Dec 11;284(50):34839–48.
- 675 31. Havel JJ, Chowell D, Chan TA. The evolving landscape of biomarkers for checkpoint  
676 inhibitor immunotherapy. Vol. 19, *Nature Reviews Cancer*. Nature Publishing Group;  
677 2019. p. 133–50.
- 678 32. Kattan J, Kattan C, Assi T. Do checkpoint inhibitors compromise the cancer patients'  
679 immunity and increase the vulnerability to COVID-19 infection? *Immunotherapy*.  
680 2020 Apr 14;0(0).
- 681 33. Airavaara M, Shen H, Kuo CC, Peränen J, Saarma M, Hoffer B, et al. Mesencephalic  
682 astrocyte-derived neurotrophic factor reduces ischemic brain injury and promotes  
683 behavioral recovery in rats. In: *Journal of Comparative Neurology*. NIH Public  
684 Access; 2009. p. 116–24.
- 685 34. Zhou L, Zhang M, Wang J, Gao J. Sars-Cov-2: Underestimated damage to nervous  
686 system. *Travel Medicine and Infectious Disease*. Elsevier USA; 2020.
- 687 35. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et  
688 al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients  
689 Hospitalized With COVID-19 in the New York City Area. *JAMA* [Internet]. 2020  
690 May 26 [cited 2020 Jun 15];323(20):2052. Available from:



- 691 <https://jamanetwork.com/journals/jama/fullarticle/2765184>
- 692 36. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DKW, et al. Detection  
693 of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. *Eurosurveillance*. 2020  
694 Jan 23;25(3).
- 695 37. Assarsson E, Lundberg M, Holmquist G, Björkesten J, Bucht Thorsen S, Ekman D, et  
696 al. Homogenous 96-Plex PEA Immunoassay Exhibiting High Sensitivity, Specificity,  
697 and Excellent Scalability. Hoheisel JD, editor. *PLoS One* [Internet]. 2014 Apr 22  
698 [cited 2020 May 27];9(4):e95192. Available from:  
699 <https://dx.plos.org/10.1371/journal.pone.0095192>
- 700 38. Kamburov A, Wierling C, Lehrach H, Herwig R. ConsensusPathDB - A database for  
701 integrating human functional interaction networks. *Nucleic Acids Res*.  
702 2009;37(SUPPL. 1):623–8.
- 703 39. Kanehisa M, Sato Y. KEGG Mapper for inferring cellular functions from protein  
704 sequences. *Protein Sci* [Internet]. 2020 Jan 29 [cited 2020 Jun 1];29(1):28–35.  
705 Available from: <https://onlinelibrary.wiley.com/doi/abs/10.1002/pro.3711>
- 706
- 707

708 **Supporting information captions**

709 Supplementary Table 1: Statistical testing of patient demographic variables

710 Supplementary Table 2: Complete differential expression analysis results

711 Supplementary Table 3: Pathway enrichment analysis results

712 Supplementary Table 4: OLINK neuronal proteins correlated with markers of neural injury

713 and astrogliosis

714

715